Immunomodulatory therapy in the early phases of multiple sclerosis;Die immunmodulatorische frühbehandlung der multiplen sklerose

Nervenheilkunde

Volumn 20, Issue 4, 2001, Pages 237-243

  Chan, A ^a   Rieckmann, P ^a   Gold, R ^a  

^a NONE

Author keywords

Beta Interferon; CHAMPS; ETOMS; MS therapy; Oxonal damage

Indexed keywords

BETA INTERFERON; IMMUNOMODULATING AGENT;

DISEASE COURSE; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REVIEW; TREATMENT PLANNING;

EID: 0034967196     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Multiple sclerosis from probable to definite diagnosis. A 7-year prospective study
2. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
3. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
4. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis
5. Acute axonal injury in multiple sclerosis
6. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients
7. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis
8. Multisequence MRI in clinically isolated syndromes and the early development of MS
9. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
10. Interferon beta 1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study
11. Relapses and progression of disability in multiple sclerosis
12. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability
13. Clinical prognostic indicators
14. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis
15. Krankheitsverlauf und prognose der multiplen sklerose
16. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
17. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
18. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis
19. Axonal pathology in multiple sclerosis. A historical note
20. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
21. Spinal cord atrophy and disability in multiple sclerosis - A new reproducible and sensitive MRI method with potential to monitor disease progression
22. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis
23. Immunmodulatorische stufentherapie der multiplen sklerose
24. Immunmodulatorische Stufentherapie der multiplen Sklerose, 1. Erg̈nzung: Dezember 2000
25. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
26. Consensus statement of the Canadian MS Clinics Network on: The use of disease modifying agents in multiple sclerosis
27. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
28. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis
29. Optic neuritis: A population-based study in Olmsted County, Minnesota
30. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsingremitting MS
31. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination
32. A longitudinal study of brain atrophy in relapsing multiple sclerosis
33. Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings
34. Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders
35. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
36. Axonal transection in the lesions of multiple sclerosis
37. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
38. The natural history of multiple sclerosis
39. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course